Cell therapy for diabetes: New data, approval, buyout; GLP-1 race in weight loss reaches new stage; FDA finally approves BioMarin’s gene therapy; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

For many of our US read­ers, this may be the start of a long week­end as we look ahead to the hol­i­day on Ju­ly 4. A sched­ul­ing note: On Mon­day, Ju­ly 3, we won’t pub­lish our ear­ly edi­tion, but our ear­ly and lat­er af­ter­noon newslet­ters will still be ar­riv­ing in your in­box­es. Have a good week­end.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN